Table 3.
ECLS strategy | Principle indication(s) |
---|---|
VA ECMO (return femoral artery) |
Default strategy for potentially reversible cardiogenic shock of any cause |
VA ECMO (return axillary artery) |
Reversible cardiogenic shock where high flows are not required |
|
Reversible cardiogenic shock with lower-limb vascular disease |
|
Reversible cardiogenic shock with poor gas exchange |
VA ECMO (return ascending aorta) |
Failure to wean from cardiopulmonary bypass where recovery expected within 7 days |
|
Salvage for small patients with cardiogenic shock where femoral arterial access inadequate |
|
Salvage for severe combined cardiac and respiratory failure |
VA–venous ECMO |
Patients developing circulatory instability on venovenous ECMO |
|
Salvage for severe combined cardiac and respiratory failure |
Venous–pulmonary artery ECMO |
Reversible RV dysfunction expected duration up to 2 weeks |
Centrimag™ (Levitronix LLC, Waltham, MA, USA) RVAD (femoral access + oxygenator) |
Reversible RV dysfunction expected duration up to 2 weeks |
Centrimag™ (Levitronix LLC) RVAD (right atrium access + oxygenator) |
Reversible isolated RV dysfunction expected duration up to 8 weeks with plan to remove oxygenator and convert to RVAD |
Centrimag™ (Levitronix LLC) hybrid (requires oxygenator) |
Severe LV after load mismatch on VA ECMO |
|
Severe combined cardiac and respiratory failure where early RV recovery is expected before intermediate term LV recovery |
Implantable LVAD + temporary RVAD (±oxygenator) | Met criteria for LVAD but unexpected reversible RV dysfunction occurred |
ECLS, extracorporeal life support; ECMO, extracorporeal membrane oxygenation; LV, left ventricular; LVAD, left ventricular assist device; RV, right ventricular; RVAD, right ventricular assist device; VA, venoarterial.